We expect CRISPR Therapeutics (CRSP) to surpass expectations when it reports third-quarter 2024 results. In the last reported quarter, the company missed on earnings by 8.76%. The Zacks Consensus Estimate for sales is pinned at $6.4 million, while the same for earnings is pegged at a loss of $1.33 per share. Factors Shaping CRSP's Upcoming Results CRISPR Therapeutics' top line currently includes grants and collaboration revenues from its partnership with large-cap biotech Vertex Pharmaceuticals (VRTX) . CRS ...

CRISPR Therapeutics (NASDAQ: CRSP ) is the market leader in transformative therapies incorporating CRISPR/Cas9 biotechnology, and their 9-year ongoing partnership with Vertex Pharmaceuticals ( VRTX ) brings great promise. Most recently, both companies received FDA (December 2023) and EMA (February 2024) approvals for Casgevy, the I have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the p ...

This company might be worth far more than many realize.If I had to buy one share of any biotech with no price restriction, I'd naturally gravitate toward the most successful companies in the industry. However, the exercise becomes more complicated if you stipulate a limit of $50 per share; most of the prominent biotech stocks are trading well above that amount.Those around that level are, disproportionately, relatively small and risky companies whose prospects don't look all that strong. Still, at least one ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $48.51, marking a -0.84% move from the previous day. This change lagged the S&P 500's daily loss of 0.18%. Elsewhere, the Dow saw a downswing of 0.8%, while the tech-heavy Nasdaq appreciated by 0.27%.The the stock of company has risen by 1.54% in the past month, leading the Medical sector's loss of 3.03% and undershooting the S&P 500's gain of 4.46%.Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its u ...

CRISPR Therapeutics AG (CRSP) closed the last trading session at $48.92, gaining 1.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $81.96 indicates a 67.5% upside potential. The average comprises 24 short-term price targets ranging from a low of $30 to a high of $199, with a standard deviation of $34.57. While the lowest estimate indicates a decline of 38.7% from the current pri ...

CRISPR Therapeutics AG (CRSP) closed at $48.05 in the latest trading session, marking a +0.47% move from the prior day. The stock's performance was ahead of the S&P 500's daily loss of 0.76%. On the other hand, the Dow registered a loss of 0.75%, and the technology-centric Nasdaq decreased by 1.01%. The the stock of company has risen by 0.18% in the past month, leading the Medical sector's loss of 3.35% and undershooting the S&P 500's gain of 4.31%. The investment community will be closely monitoring the pe ...

They won't remain southbound forever. CRISPR Therapeutics (CRSP 3.22%) and Moderna (MRNA 2.57%) have much in common. They're both innovative biotechs working in relatively newer niches of this booming industry. However, they've moved in the wrong direction this year. CRISPR's shares are down by 27% year to date, and Moderna's are down by 41%. Regardless of their performances so far in 2024, both stocks are worth investing in this month. Read on to find out why. 1. CRISPR Therapeutics CRISPR Therapeutics rec ...

CRISPR Therapeutics is trading around multiyear lows. Finding an undervalued growth stock can lead to some oversize returns in the long run. In some cases, it can be as simple as focusing on sectors of the market that might not be getting much attention of late, and thus could make for attractive under-the-radar investments right now. One stock that has been struggling and that arguably should be doing a lot better these days is CRISPR Therapeutics (CRSP 1.05%). There was a lot of excitement around the heal ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $45.71, demonstrating a +0.29% swing from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.01% for the day. Elsewhere, the Dow saw an upswing of 0.09%, while the tech-heavy Nasdaq appreciated by 0.08%. Coming into today, shares of the company had gained 0.13% in the past month. In that same time, the Medical sector lost 3.6%, while the S&P 500 gained 1.21%. Analysts and investors alike will be ke ...

Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks. It's not fun missing out when a hot stock goes wild. The viral popularity of injectable diabetes and weight loss drugs, called GLP-1s, propelled pharmaceutical stock Novo Nordisk to over 350% in returns over the past five years. That sizeable return beat the broader market by a comfortable margin. But you needn't worry if you feel that you've missed out. The great thing about investing is th ...